The purpose of the this study is to evaluate the safety of efficacy of APC-111 775 mg MP tablet once daily dosing for 7 days for treating patients with strep throat. The evaluation will look to confirm if APC-111 eliminates the bacterial infection (Streptococcus pyogenes).

Ages Eligible for Study:  12 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Give informed consent, assent and patient authorization
• Age 12 and over
• A clinical diagnosis of acute pharyngitis or tonsillitis
• A positive rapid Strep test
• Can swallow the oral study dosage forms
• Females must have a negative urine pregnancy test and be using acceptable birth control if sexually active

Exclusion Criteria:

• Chronic or recurrent odynophagia
• Need for hospitalization or IV antimicrobial therapy
• Pharyngitis known or suspected due to a pathogen resistant to beta-lactam antimicrobials
• Known carrier of S. pyogenes
• Allergies to penicillin or other beta-lactam antibiotics
• Any serious illness or concomitant condition that the investigator judges will preclude inclusion to the study
• Seizure disorder
• Pregnant or nursing
• Expectation of additional systemic antibacterials would be required for another condition
• Current drug or alcohol abuse
• Any experimental drug or device within the last 30 days
• Prior systemic antibiotic therapy within the last 30 days
• Hospitalization within the last month which included antibacterial therapy
• The presence of clinically significant hematologic conditions, etc
• Probenecid treatment